<i>In Vitro</i> Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases

Ryan K. Shields, M. Hong Nguyen, Ellen G. Press, Liang Chen, Barry N. Kreiswirth, Cornelius J. Clancy

Antimicrobial Agents and Chemotherapy · 2017 · 105 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

ABSTRACT Ceftazidime-avibactam resistance is mediated by bla KPC-3 mutations, which restore carbapenem susceptibility. We subjected Klebsiella pneumoniae isolates with different bla KPC-3 mutations ( n = 5) or wild-type bla KPC-3 ( n = 2) to serial passages with meropenem. The meropenem MIC against each isolate increased. Mutations in the ompK36 porin gene evolved in 5 isolates. Among isolates with D179Y substitutions in KPC-3, bla KPC-3 mutations reverted to wild type, were replaced by new mutations, or were retained. Carbapenem treatment of ceftazidime-avibactam-resistant K. pneumoniae infections may select for carbapenem resistance.

References

15